PrEP Demonstration Project (PRELUDE Study)
Significant increases in HIV diagnoses among gay and other homosexually active men, in Australia and internationally, have been observed since the late 1990s. The levels of high HIV risk sexual practices among gay men have also increased, particularly unprotected anal intercourse (UAI). Nationally, over three quarters of the new HIV infections diagnosed annually are among men who have sex with men (MSM). The proportion of heterosexual men and women among those diagnosed with HIV annually has also increased in recent years. Despite successes in some situations, HIV transmission has not been adequately reduced by the prevention methods available to those at risk, such as education, condoms, and treatment of sexually transmitted infections (STIs).
The effectiveness of daily oral antiretroviral medications (ARVs) as preexposure prophylaxis of HIV (PrEP) has now been established by clinical trials in both heterosexual adults and homosexual men. Whether PrEP confers high rates of protection in real life situations and is a feasible strategy to implement still requires further investigation. Through its "HIV prevention strategy 2015: New era," NSW Health committed to consider how to most appropriately and efficiently implement PrEP in line with evidence. This commitment translated in the support to this PrEP demonstration project.
This demonstration project is designed to evaluate the off-label provision of daily combination of tenofovir disoproxil fumarate and emtricitabine (TDF/FTC, known as TRUVADA) as PrEP to a sample of sero-negative individuals at high risk for HIV infection in clinical settings in New South Wales. The project will inform policy development regarding primary HIV prevention with PrEP.
This is an open-label, single-arm treatment evaluation study. All consenting and eligible HIV negative participants will receive TRUVADA prescribed for daily administration orally. At each followup visit, the following procedures will be conducted: clinical evaluations/ procedures, laboratory evaluations/ procedures, testing for HIV, STIs, hepatic and renal function, assessment for adherence to the prescribed medication, side effects, eligibility for next TRUVADA prescription, and willingness to continue on PrEP.
As a study requirement, participants will be offered a self-administered assessment of behaviour, lifestyle and attitudes which will be conducted ideally within two and no more than seven days of the clinic visit in the participant's private space.
Analyses will include: the feasibility of PrEP delivery, adherence to the study medication, safety and tolerability, the effects of PrEP use on behavior, and statistical analyses of the risk of HIV seroconversion.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||Implementation of HIV Preexposure Prophylaxis With Antiretroviral Medications Among People at High Risk for HIV Infection: A Demonstration Project|
- Time to accrual [ Time Frame: Approximately 18 months ] [ Designated as safety issue: No ]Time to accrual of 300 person-years of follow-up on TRUVADA. Each participant will receive TRUVADA for a maximum of 12 months, and will be followed for an additional three months after discontinuation. (Primary endpoint: feasibility of the process of PrEP delivery in health care settings in NSW)
- Seroconversion-free time on PrEP [ Time Frame: Approximately 18 months ] [ Designated as safety issue: No ]Seroconversion-free time on PrEP (Primary endpoint: feasibility of the process of PrEP delivery in health care settings in NSW)
- Time to TRUVADA discontinuation [ Time Frame: Approximately 18 months ] [ Designated as safety issue: No ]Time to TRUVADA discontinuation (primary endpoint: adherence)
- Prescribed doses taken [ Time Frame: Approximately 18 months ] [ Designated as safety issue: Yes ]Percentage of prescribed doses taken orally in the prescribed period (primary endpoint: adherence)
- Incidents of HIV seroconversion [ Time Frame: Approximately 24 months ] [ Designated as safety issue: Yes ]Incidence of HIV seroconversion among study participants during the course of their study participation and in six months following PrEP discontinuation (primary endpoint: safety and side effects)
- Incidents of rectal gonorrhea and chlamydia [ Time Frame: Approximately 18 months ] [ Designated as safety issue: Yes ]New rectal gonorrhoea and chlamydia infections (primary endpoint: behavioral effects of PrEP use)
- Serious adverse reactions [ Time Frame: Approximately 18 months ] [ Designated as safety issue: Yes ](primary endpoint: safety and side effects)
- Adverse events [ Time Frame: Approximately 18 months ] [ Designated as safety issue: Yes ]Any adverse events leading to interruption or discontinuation of the study product (TRUVADA) (primary endpoint: safety and side effects)
|Study Start Date:||September 2014|
|Estimated Primary Completion Date:||September 2016 (Final data collection date for primary outcome measure)|
Experimental: Treatment group (TRUVADA)
Homosexual men and heterosexual men and women at high risk of HIV infection
Drug: emtricitabine/tenofovir disoproxil fumarate
Please refer to this study by its ClinicalTrials.gov identifier: NCT02206555
|Australia, New South Wales|
|RPA Sexual Health||Not yet recruiting|
|Camperdown, New South Wales, Australia, 2050|
|Contact: David Templeton, MBChB, PhD + 61 2 9515 1200|
|Principal Investigator: David Templeton, MBChB, PhD|
|St Vincent's Hospital HIV, Immunology and Infectious Disease Unit||Not yet recruiting|
|Darlinghurst, New South Wales, Australia, 2010|
|Contact: Andrew Carr, MD +61 2 8382 3707|
|Contact: John McAlister, RN, MSc +61 2 8382 3707|
|Principal Investigator: Andrew Carr, MD|
|Sub-Investigator: John McAlister, RN, MSc|
|Western Sydney Sexual Health Centre||Not yet recruiting|
|Parramatta, New South Wales, Australia, 2150|
|Contact: Catriona Ooi, MBBS, MMed +61 2 9843 3124|
|Principal Investigator: Catriona Ooi, MBBS, MMed|
|Sydney Sexual Health Centre||Not yet recruiting|
|Sydney, New South Wales, Australia, 2000|
|Contact: Anna McNulty, MBBS, MMed +61 2 9382 7440|
|Principal Investigator: Anna McNulty, MBBS, MMed|
|Study Chair:||Iryna Zablotska, MD, MPH, PhD||The Kirby Institute for Infection and Immunity in Society|